Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The Chinese University of Hong Kong (CUHK) said Wednesday that it has struck a deal with startup MicroSigX Biotech Diagnostic to offer an investigational microbiome test for autism to 200 eligible children under a pilot project.

Solvd Health said Wednesday that its pharmacogenomics (PGx) test PreScript has received approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP).

"In the past, when we talked about sexually active populations, we mainly referred to people aged 20 to 49, who accounted for the majority of HIV infections. But now, infection rates among people aged 50 and above are increasing."

Becton Dickinson said Monday that its partner Certest Biotec has received In Vitro Diagnostic Medical Device Regulation certifications in Europe for two infectious disease assays.

AI biotechnology startup Valinor has raised $13 million in seed funding to further develop its multiomics-powered machine learning models to boost clinical trial success rates for drug development.

Roche Diagnostics’ Elecsys® Alzheimer’s disease (AD) cerebrospinal fluid (CSF) test panel has received approval from the National Medical Products Administration (NMPA) for market launch in China.

Exact Sciences is building evidence on the ability of its Oncodetect minimal residual disease (MRD) test to determine the risk of distant recurrence in breast cancer patients in the hopes of expanding its adoption and reimbursement in this setting.

Helio Genomics said Monday that it has partnered to offer its LiverTrace at-home blood test for liver cancer in partnership with liver health telemedicine firm LiverRight.

Lunit on Monday said it has started a collaboration with Daiichi Sankyo to use its artificial intelligence-based digital pathology tools to advance translational research and biomarker discovery for two of Daiichi's oncology pipeline programs.

Roche said Monday that the US Food and Drug Administration has approved the company's Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and Ventana HER2 Dual ISH DNA Probe Cocktail tests, clearing them for identifying HER2-positive metastatic breast cancer (mBC) patients who may be eligible for treatment with AstraZeneca's Enhertu (trastuzumab deruxtecan).